在2型糖尿病中GLP-1受体激动剂和动脉瘤破裂风险:多中心回顾性研究
Sean Y Li1, Anisha Sonti1, David C Kaelber2
1Case Western Reserve University School of Medicine, Cleveland, OH, USA.
概括
类似葡萄糖-1受体激动剂 (GLP-1RAs) 可能降低2型糖尿病患者内动脉瘤 (IA) 破裂的风险. 这项研究发现GLP-1RA的使用与下大脑底下出血 (SAH) 的发病率较低有关.
科学领域:
- 心血管研究研究心血管研究
- 内分泌学 在内分泌学.
- 神经外科 神经外科
背景情况:
- 内动脉瘤 (IAs) 影响高达3%的人口,在破裂时带来显著的发病率和死亡率风险.
- 临床前研究表明,葡萄糖类-1受体激动剂 (GLP-1RAs) 可能提供血管保护性益处.
- 在大型人群中,GLP-1RAs在预防IA破裂中的作用仍然被低估.
研究的目的:
- 调查GLP-1RA使用与2型糖尿病 (T2DM) 和未破裂IA患者动脉瘤破裂风险之间的关联.
- 评估GLP-1RAs在内动脉瘤管理的背景下潜在的血管保护作用.
主要方法:
- 一项回顾性队列研究利用了TriNetX研究网络,包括T2DM和未破裂IA的成年人 (2008-2025年).
- 患者被分为GLP-1RA使用者和非使用者.
- 倾向性得分匹配 (PSM) 在人口统计学,并发症和药物方面平衡了队列;在3年和5年的随访中,主要结局是非创伤性脑下垂体出血 (SAH).
主要成果:
- 这项研究确定了24,776名T2DM患者具有未破裂的IA;3119人是GLP-1RA用户.
- 在 1:1 PSM 后,每个队列中有 2651 名患者. GLP-1RA处方与3年 (HR 0.62) 和5年 (HR 0.65) 的SAH风险显著降低有关.
- 两组之间没有观察到随访实验室值的显著差异.
结论:
- 在T2DM患者中,GLP-1RA的处方与未破裂的IA显示出与降低动脉瘤破裂风险的相关性.
- 研究结果表明GLP-1RA可能对内动脉瘤有稳定作用.
- 需要进一步的前性成像研究来证实这种关联并阐明潜在的机制.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
5.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.1K
Glucagon-like Receptor Agonists
1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
Drug-Receptor Interaction: Agonist
4.2K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.2K
Types of Receptors: Internal Receptors
32.7K
Many cellular signals are hydrophilic and cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind intracellular receptors that reside within the cell cytoplasm or nucleus. Many mammalian steroid hormones and nitric oxide (NO) gas use this cell signaling mechanism.
Similar to membrane-bound receptors, the binding of a ligand to the intracellular receptor of causes a conformational change in the...
Similar to membrane-bound receptors, the binding of a ligand to the intracellular receptor of causes a conformational change in the...
32.7K
Predicting Products: SN1 vs. SN2
17.4K
Nucleophilic substitution reactions of alkyl halides can proceed via an SN1 or an SN2 mechanism. While in SN2 reactions, the nucleophile attacks the substrate simultaneously as the leaving group departs, in SN1 reactions, the substrate first dissociates to give the carbocation intermediate. Various factors such as the structure of the substrate, the strength of the nucleophile, and the nature of the solvent promote one mechanism over the other.
With increased substitution on the alkyl halide,...
With increased substitution on the alkyl halide,...
17.4K
Types of Receptors: Cell Surface Receptors
27.6K
Cell-surface receptors, also known as transmembrane receptors, are cell surface, membrane-anchored (integral) proteins that bind to external ligand molecules. This type of receptor spans the plasma membrane and performs signal transduction, converting an extracellular signal into an intracellular signal. Ligands that interact with cell-surface receptors do not have to enter the cell that they affect. Cell-surface receptors are also called cell-specific proteins or markers because they are...
27.6K


